Eyepoint Pharmaceuticals logo
EYPTEyepoint Pharmaceuticals
Trade EYPT now
Eyepoint Pharmaceuticals primary media

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals (NASDAQ:EYPT) focuses on developing and commercializing therapeutics for eye diseases. Specializing in sustained release drug delivery products, this company is dedicated to advancing treatments for serious eye disorders. Their project portfolio includes innovative technologies aimed at improving the lives of patients with chronic eye conditions. Eyepoint Pharmaceuticals is actively engaged in research, development, and commercialization stages to bring its unique products to market. The company's objectives are centered on achieving excellence in eye care, expanding their product offerings, and reaching a broader patient population.

What is EYPT known for?

Snapshot

Public US
Ownership
1987
Year founded
140
Employees
Watertown, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Products and/or services of Eyepoint Pharmaceuticals

  • YUTIQ - A treatment for chronic non-infectious uveitis affecting the posterior segment of the eye.
  • DEXYCU - An FDA-approved intraocular product for the treatment of postoperative inflammation.
  • ILUVIEN - A micro-insert for diabetic macular edema, licensed to Alimera Sciences in certain markets.
  • EYP-1901 - A potential treatment for wet age-related macular degeneration, utilizing a bioerodible Durasert technology.
  • Development of treatments for ocular diseases using Durasert and bioerodible sustained release drug delivery platforms.
  • Partnerships for leveraging its drug delivery technologies in ophthalmology and other therapeutic areas.

Eyepoint Pharmaceuticals executive team

  • Dr. Jay S. Duker M.D.President, CEO & Director
  • Mr. George O. Elston CPAExecutive VP & CFO
  • Dr. Ramiro Ribeiro M.D., Ph.D.Chief Medical Officer
  • Dr. Marcia Sellos-Moura Ph.D.Chief Scientific Officer
  • Mr. Ron I. Honig Esq.Chief Legal Officer & Company Secretary
  • Ms. Jennifer LeonardChief People Officer & Senior VP of IT
  • Mr. David Scott Jones M.A.Senior VP & Chief Commercial Officer
  • Ms. Isabelle LefebvreChief Regulatory Officer
  • Mr. Michael J. MaciocioChief Manufacturing Officer
  • Dr. Anna KluczewskaCEO of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.